Article Text

Download PDFPDF
Benefits of Enhancing the Platinum-Free Interval in the Treatment of Relapsed Ovarian Cancer: More Than Just a Hypothesis?
  1. Jonathan A. Ledermann, BSc, MD
  1. UCL Cancer Institute, University College London, London, United Kingdom.
  1. Address correspondence and reprint requests to Jonathan A. Ledermann, BSc, MD, UCL Cancer Institute, UCLH & UCL Biomedical Research Centre, London, United Kingdom. E-mail: j.ledermann{at}


There is some evidence from in vitro studies as well as case series that patients with documented platinum resistance will respond to platinum after a nonplatinum drug. In addition, retrospective case studies have demonstrated the difficulty in determining if delaying second platinum is detrimental or beneficial. For that reason, a prospective Italian randomized trial conducted by the Multicenter Italian Trials in Ovarian Cancer (MITO) Group (MITO-8), comparing nonplatinum with platinum-based therapy is being performed to assess the effects of delaying platinum on survival.

  • Platinum sensitivity
  • Recurrent ovarian cancer
  • Trabectedin

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Disclosure: Editorial assistance for the preparation of this manuscript was funded by PharmarMar.